T7 RNA polymerase mutant with improved thermal stability and application thereof
By screening and optimizing T7 RNA polymerase mutants, the problem of insufficient thermal stability of existing T7 RNA polymerase under high temperature conditions was solved, the thermal stability and application performance of the enzyme were improved, and the by-products in the RNA synthesis process was reduced. Content, suitable for the research and preparation of mRNA vaccines and drugs.
Patent Information
- Application Number
- CN202310558557.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-15
- Publication Date
- 2024-11-15
AI Technical Summary
The existing T7 RNA polymerase is insufficient thermal stability under high temperature conditions, which is difficult to meet the current research and application needs. At the same time, the production of by-products during RNA synthesis affects the research and preparation of mRNA vaccines and drugs.
By screening and optimizing T7 RNA polymerase mutants, mutations in specific amino acid residues (such as I217L, S397W, S430P, S633P, Q786L) improve the thermal stability and enzyme activity of the enzyme, and the droplet microfluidic cell sorting method is used Mutants with high thermal stability were screened.
The T7 RNA polymerase mutants provided showed good application performance at both 37°C and 50°C, reducing the dsRNA by-product content of RNA products and improving the 3' consistency of the product. They are suitable for mRNA vaccines and drugs. Research and preparation.
Smart Images

Figure CN118956809A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of genetic engineering and enzyme engineering, and in particular to a T7 RNA polymerase mutant with improved thermal stability and application thereof. Background Art
[0002] T7 RNA polymerase (T7 RNAP) is derived from Escherichia coli bacteriophage T7 and is a DNA-dependent single-subunit RNA polymerase that highly specifically recognizes the T7 promoter sequence. The enzyme can be used not only for in vitro RNA synthesis, such as gRNA, siRNA, and isotope-labeled or non-isotope-labeled RNA probe synthesis, but also for synthesizing capped mRNA with the participation of cap analog for intracellular or in vivo expression and mRNA vaccine and drug research; it can also be used for isothermal amplification, such as sequence-specific nucleic acid in vitro amplification (Nucleic Acid Specific-Based Amplification, NASBA) and transcription-mediated amplification (Transcription mediated amplification, TMA).
[0003] Although the wild-type T7 RNAP has the advantages of high transcription efficiency and strong extension ability, there are some shortcomings that cannot be ignored in practical application research, such as the optimal reaction temperature is around 37°C, which is difficult to be compatible with other high-temperature resistant enzymes to establish an efficient "one-pot" multifunctional enzyme catalytic system; and many by-products may be produced in the process of RNA synthesis, including short aborted fragments, 3' end extension products, dsRNA, etc. produced during the transcription initiation process, which is very unfavorable for the research and preparation of mRNA vaccines and drugs. However, with the rapid development of mRNA drugs and molecular diagnostic technologies, the wild-type T7 RNA polymerase currently on the market cannot fully meet the growing research needs. Therefore, it is urgent to optimize and improve T7RNAP so that it can not only tolerate a wider range of reaction temperatures and maintain efficient transcription, but also reduce the problem of RNA product heterogeneity.
[0004] In the existing technology, CN111212905A provides a T7 RNAP mutant that reduces dsRNA contaminants and concatenated transcripts generated during in vitro transcription reactions; and CN112831484A provides a method suitable for the synthesis of RNA containing internal termination signals and RNA with hairpin structures at the ends, which can synthesize Cas9sgRNA with higher purity than T7 RNAP-WT, but the thermal stability of these mutants is not supported by data, and it is difficult to meet the research and application requirements under high temperature conditions. Although there are a small number of heat-resistant T7 RNA polymerase products on the market, it is still difficult to meet the current research and application needs.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] The first purpose of the present invention is to provide a T7 RNA polymerase mutant, which has higher thermal stability and enzyme activity, thereby alleviating the problem of insufficient heat-resistant T7 RNA polymerase products on the market.
[0007] The second object of the present invention is to provide a polynucleotide, a vector and a cell related to the above-mentioned T7 RNA polymerase mutant.
[0008] The third object of the present invention is to provide a method for screening T7 RNA polymerase mutants.
[0009] The fourth object of the present invention is to provide a method for synthesizing a polynucleotide.
[0010] The fifth object of the present invention is to provide an application of the above-mentioned T7 RNA polymerase mutant or the synthesis method of the above-mentioned polynucleotide in at least one of mRNA vaccine preparation, nucleic acid drug preparation, gene editing and protein expression system construction.
[0011] The sixth object of the present invention is to provide a kit for polynucleotide synthesis.
[0012] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:
[0013] According to one aspect of the present invention, the present invention provides a T7 RNA polymerase mutant, the T7 RNA polymerase mutant corresponds to the amino acid sequence shown in SEQ ID NO.1, corresponding to the amino acid sequence shown in SEQ ID NO.1, and has at least one of the following amino acid residues: L at position 217, A or W at position 397, and A or W at position 579;
[0014] Furthermore, it has at least 80% identity with SEQ ID NO.1.
[0015] Preferably, the T7 RNA polymerase mutant further comprises at least one of the following amino acid residues: corresponding to the amino acid sequence shown in SEQ ID NO.1, at least one of positions 369, 430, 633, 786, 744, 723 and 724 is different from SEQ ID NO.1;
[0016] Preferably, the 633rd position corresponding to the amino acid sequence shown in SEQ ID NO.1 is a non-polar hydrophobic amino acid; more preferably, it is P, L, V, M or F; and even more preferably, it is P;
[0017] Preferably, the 744th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is R, P or L; more preferably R;
[0018] Preferably, the 786th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is Y or a non-polar hydrophobic amino acid; more preferably Y, L, M, W or F; and even more preferably L;
[0019] Preferably, the 723rd position corresponding to the amino acid sequence shown in SEQ ID NO.1 is E or S; more preferably, E;
[0020] Preferably, position 369 corresponding to the amino acid sequence shown in SEQ ID NO.1 is T or E;
[0021] Preferably, the 430th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is P;
[0022] Preferably, the 724th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is N;
[0023] Preferably, the 397th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is W;
[0024] Preferably, the 579th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is W.
[0025] Preferably, the T7 RNA polymerase mutant is selected from any one of the following:
[0026] (a) at least one I217L mutation is present in the amino acid sequence of SEQ ID NO.1;
[0027] (b) at least S397W mutation is present in the amino acid sequence shown in SEQ ID NO.1;
[0028] (c) at least N579W mutation is present in the amino acid sequence shown in SEQ ID NO.1;
[0029] (d) at least I217L, S397W, S430P, S633P and Q786L mutations are present in the amino acid sequence of SEQ ID NO.1;
[0030] (e) at least I217L, S397W, S430P, S633P, Q786L and N579W mutations are present in the amino acid sequence of SEQ ID NO.1;
[0031] (f) at least I217L, S397W, S430P, S633P, Q786L and Q744R mutations are present in the amino acid sequence of SEQ ID NO.1;
[0032] (g) at least I217L, S397W, S430P, S633P, Q786L, C723E and A724N mutations are present in the amino acid sequence of SEQ ID NO.1;
[0033] Preferably, the amino acid sequence of the T7 RNA polymerase mutant is shown in SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.15 or SEQ ID NO.17.
[0034] According to one aspect of the present invention, the present invention also provides a polynucleotide encoding the aforementioned T7 RNA polymerase mutant.
[0035] According to one aspect of the present invention, the present invention also provides a vector, which carries the aforementioned polynucleotide.
[0036] According to one aspect of the present invention, the present invention also provides a cell, which carries the aforementioned polynucleotide or the aforementioned vector, or expresses the aforementioned T7 RNA polymerase mutant.
[0037] According to one aspect of the present invention, the present invention also provides a method for screening T7 RNA polymerase mutants, comprising amplifying a polynucleotide encoding T7 RNA polymerase in a reaction system containing 0.1 mM to 0.6 mM manganese ions, then transforming a vector carrying the amplification product into cells, inducing expression in the cells and sorting target cells using a droplet microfluidic cell sorting method; in the in vitro incubation step of the droplet microfluidic cell sorting, heat treating the droplets.
[0038] According to one aspect of the present invention, the present invention also provides a method for synthesizing a polynucleotide, comprising using an enzyme system comprising the aforementioned T7 RNA polymerase mutant to catalyze a synthesis reaction.
[0039] According to one aspect of the present invention, the present invention also provides an application of the aforementioned T7 RNA polymerase mutant, or the aforementioned polynucleotide synthesis method in any one of the following: at least one of mRNA vaccine preparation, nucleic acid drug preparation, gene editing and protein expression system construction.
[0040] According to one aspect of the present invention, the present invention also provides a kit for polynucleotide synthesis, the kit comprising the aforementioned T7 RNA polymerase mutant.
[0041] Compared with the prior art, the present invention has the following beneficial effects:
[0042] The present invention successfully established a high-throughput T7RNAP mutant library screening platform by encapsulating single cells and reaction systems using the FADS platform. Using the platform, the present invention screened the following T7 RNA polymerase mutants, which correspond to the amino acid sequence shown in SEQ ID NO.1, and have at least one of the following amino acid residues: L at position 217, A or W at position 397, and A or W at position 579; and have at least 80% identity with SEQ ID NO.1. The T7 RNA polymerase mutant provided by the present invention has good thermal stability and a good temperature adaptability range, and can react not only under conventional 37°C conditions, but also under high temperature 50°C conditions.
[0043] The T7 RNAP mutant provided by the present invention also has good application performance under 37°C conditions, and the T7 RNA polymerase combination mutant containing multiple mutation sites has a purity of in vitro transcription product that is better than the wild-type T7 RNA polymerase or the reported T7 RNA polymerase mutant. The T7 RNA polymerase mutant provided by the present invention still has very good application performance under 50°C conditions, the yield of synthetic RNA is significantly better than the wild type and the reported mutant, the product purity is not worse than the prior art, and the synthesized mRNA has fewer dsRNA byproducts, which will produce lower immunogenicity, and the 3' consistency of the product is significantly improved compared to the prior art. These indicators are very beneficial for the research and production of mRNA vaccines and drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0045] Figure 1 This is a schematic diagram of the T7 RNAP recombinant expression vector;
[0046] Figure 2 The flowchart of microdroplet sorting based on aptamer fluorescence activation;
[0047] Figure 3A This is an SDS-PAGE image of the T7 RNAP mutant purified by nickel column. The sample names corresponding to the lanes in the figure are as follows: 1: before column; 2: flow-through; 3: Triton wash; 4: 50mM imidazole elution; 5: 100mM imidazole elution; 6: 150mM imidazole elution; 7: 200mM imidazole elution; 8: 500mM imidazole elution; 9: Marker;
[0048] Figure 3B This is an SDS-PAGE image of the T7 RNAP mutant purified by nickel column. The sample names corresponding to the lanes in the figure are as follows: 1: before column; 2: flow-through; 3: Triton wash; 4: 50mM imidazole elution; 5: 100mM imidazole elution; 6: 150mM imidazole elution; 7: 500mM imidazole elution; 8: Marker;
[0049] Figure 4A This is a graph showing the changes in protein concentration of wild-type T7 RNAP versus fluorescence intensity when the relative activities of different mutants were determined by real-time fluorescence method;
[0050] Figure 4B The standard curve of protein concentration and fluorescence intensity of wild-type T7 RNAP;
[0051] Figure 5 This is a graph showing the results of detecting the dsRNA content in the IVT product of T7 RNAP mutants. The T7 RNAP mutants corresponding to the numbers in the figure are as follows: 0: WT; 1: S430P; 2: S633P; 3: Q786L; 4: I217L; 5: S397W; 6: I217L / S397W / S430P / S633P / Q786L; 7:
[0052] I217L / S397W / S430P / S633P / Q786L / N579W; 8: I217L / S397W / S430P / S633P / Q786L / Q744R; 9:
[0053] I217L / S397W / S430P / S633P / Q786L / C723E / A724N;
[0054] Fig. 6A This is the 3' consistency test result of IVT product of T7 RNAP wild type at 37℃;
[0055] Figure 6B This is the 3' consistency test result of IVT product of T7 RNAP single point mutant I217L at 50℃;
[0056] Figure 6C This is the 3' consistency test result of IVT product of T7 RNAP single point mutant S397W at 50℃. DETAILED DESCRIPTION
[0057] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0058] It should be noted that the abbreviations of amino acid residues herein are the same as the general definitions in the art, and the full names are still indicated in brackets after the abbreviations in some records herein. "Amino acid residue" and "amino acid" can be used interchangeably herein. The amino acid sequence herein starts from the nitrogen terminus.
[0059] In some optional embodiments, a method for screening T7 RNA polymerase mutants is provided, including amplifying a polynucleotide encoding T7 RNA polymerase in a reaction system containing manganese ions, then transforming a vector carrying the amplified product into cells, and sorting target cells using a droplet microfluidic cell sorting method after inducing expression; the concentration of manganese ions in the reaction system is 0.1-0.6 mM, preferably 0.2 mM-0.3 mM. Droplet microfluidic cell sorting is based on a microfluidic ultra-high throughput fluorescence-activated droplet sorting platform (Fluorescence-Activated Droplet Sorting, FADS), and the FADS screening process includes three steps: droplet encapsulation and incubation of single cells, incubation and reaction, and ultra-high throughput screening of single cell droplets after the reaction. FADS can encapsulate and culture single cells, use specific fluorescent substrates to perform fluorescent quantification of the production of secondary metabolites or specific enzymes of single cells, and sort and collect droplets whose fluorescence intensity meets the screening threshold through the screening platform, and finally obtain a large number of candidate droplets. This screening method has the advantages of high throughput and strong specificity.
[0060] In an optional embodiment, the heat treatment condition is 40-50° C. for 5-10 min, preferably 45° C. for 7 min.
[0061] In an alternative embodiment, the target cells are the 0.4% to 0.45% of droplet-encapsulated cells that exhibit the highest viability.
[0062] In an optional embodiment, the amplified polynucleotide encoding T7 RNA polymerase has a nucleotide sequence as shown in SEQ ID NO.2, and expresses a wild-type T7 RNA polymerase having an amino acid sequence as shown in SEQ ID NO.1.
[0063] In an optional embodiment, the method further includes at least one step of: isolating a target fragment from a target cell sorted by a droplet microfluidic cell sorting method, transforming the fragment into another cell, and screening the cell again after culturing the fragment.
[0064] In an optional embodiment, the T7 RNA polymerase mutants expressed by the positive cells are collected, the system containing the T7 RNA polymerase mutants is heat-treated, and then the enzyme activity is measured, and the positive clones with an enzyme activity of at least 1.5 times that of the wild type are sequenced.
[0065] In one embodiment, the T7 RNA polymerase mutants were screened using the following scheme:
[0066] First, the T7 RNAP gene (SEQ ID NO. 2) was amplified by PCR using the recombinant vector pQE-80L-T7 RNAP containing the wild-type T7 RNAP gene as a template. 2+ The concentration was used to obtain amplification products with different mutation degrees; the products were then connected to the vector pQE-80L to construct a recombinant expression vector, which was electroporated into competent E. coli 10G. The library capacity was calculated based on the clones grown. 6 The above results show that the Mn with a mutation frequency of 2 to 3 bases per gene is preferred. 2+ The concentration is 0.2mM-0.3mM.
[0067] Then, the obtained mixed plasmid mutant library was electroporated into fresh E. coli BL21 (DE3) competent cells to obtain 10 7 A mutant library of clones of about 100 μg / mL was prepared. E. coli was induced and expressed according to the protein expression steps, and the single cells and reaction system were encapsulated using the FADS platform. The single cell encapsulation rate was controlled at about 10% to improve the accuracy of screening. During in vitro incubation, the droplets were treated at a temperature of about 45°C for an appropriate time, and the activity was reduced to about one-third of the original to achieve the effect of high temperature treatment, and then incubated at 37°C for 3 hours.
[0068] Before using FADS to sort the mutant library, the most suitable laser spot position, sorting speed and other conditions are determined by sorting FITC and ink. Then the incubated microdroplets are injected into the detection and sorting chip. The droplets of about 0.42% showing the highest activity are collected in a 1.5mL centrifuge tube, and the positive gene is recovered by PCR. The target fragment is treated with BamHI and HindIII double enzymes and reconstructed into the pQE-80L linearized vector. The ligated vector is transformed into the BL21 (DE3) competent state again, and the single clone grown on the plate is picked for rescreening.
[0069] During the sorting process, several rounds of sorting were performed on the transformed mutant libraries of different batches, and the obtained positive genes were mixed and recovered to ensure that more beneficial mutation points could be sorted. From the clones obtained in the previous round, fresh monoclones were picked in a 96-well plate, and the wild-type BL21 (DE3) -T7 RNAP monoclone was used as a control. After induction and expression, the crude enzyme solution was prepared by lysing the cell lysate, and the crude enzyme solution was heat-treated at 45 ° C for 5 minutes, and then quickly placed on ice, and then the crude enzyme solution was transferred to a 384-well plate, and the enzyme activity was determined using the STAR system (iSpinach aptamer-based monitoring of transcription activity in real-time, STAR, see application number: CN202211274914.8, the invention name is "A detection method for real-time monitoring of in vitro transcribed synthetic RNA", the introduction and use of the system are detailed in CN115896213A text). Then, the mutants whose residual activity after heat treatment was at least 1.5 times that of the wild type were sequenced, and the distribution of mutation points was analyzed based on the sequencing results.
[0070] According to the distribution of the above mutation points, a recombinant expression vector carrying a nucleotide sequence encoding a T7 RNAP mutant was constructed and transformed into BL21 (DE3) Escherichia coli competent cells to obtain recombinant strains of T7 RNP wild type and mutant, induced expression and prepared T7 RNAP mutants by protein purification. Then, a single-stranded RNA aptamer was synthesized by in vitro transcription reaction, and the single-stranded RNA could bind to a specific chemical small molecule DFHBI to produce a significant fluorescence signal enhancement. The relative activity of different mutants and T7 RNAP-WT was determined by monitoring the change of real-time fluorescence during the reaction. Furthermore, the Tm values of different mutants were determined by differential scanning fluorescence by combining the T7 RNAP mutant protein solution with Sypro Orange dye. The application performance of the T7 RNAP mutant was achieved by analyzing the products synthesized by in vitro transcription reaction (IVT), including IVT yield, product purity, dsRNA content in the product and 3' end consistency index of the product.
[0071] In the above embodiment, multiple mutation sites that can improve the thermal stability of the T7 RNA polymerase mutant are screened out. Therefore, the present invention also provides a T7 RNA polymerase mutant screened out by the above screening process. The T7 RNA polymerase mutant described herein is a polypeptide that has at least one amino acid residue difference compared to the wild-type T7 RNA polymerase. In an optional embodiment, the amino acid sequence of the wild-type T7 RNA polymerase is shown in SEQ ID NO.1.
[0072] The T7 RNA polymerase mutant provided by the present invention has at least one of the following amino acid residues: corresponding to the amino acid sequence shown in SEQ ID NO.1, L (leucine) at position 217, A (alanine) or W (tryptophan) at position 397, and A (alanine) or W (tryptophan) at position 579. The T7 RNA polymerase mutant containing the aforementioned amino acid residues has good thermal stability.
[0073] The amino acid sequence corresponding to SEQ ID NO.1 as described herein refers to the amino acid residue determined by the position number of the position in the amino acid sequence shown in SEQ ID NO.1 when the T7 RNA polymerase mutant is aligned with the amino acid sequence shown in SEQ ID NO.1. For example, when one or more amino acid residues are missing at the nitrogen end of the T7 RNA polymerase mutant, the position number of a certain amino acid residue in the amino acid sequence shown in SEQ ID NO.1 corresponding to the T7 RNA polymerase mutant in SEQ ID NO.1 is different from the position number of the position in the T7 RNA polymerase mutant, for example, when the nitrogen end of the T7 RNA polymerase mutant lacks N amino acid residues, an amino acid residue is located at the i-th position in the amino acid sequence shown in SEQ ID NO.1 and is located at the iN-th position in the amino acid sequence of the T7 RNA polymerase mutant. The amino acid residue is defined herein by its position in the amino acid sequence corresponding to SEQ ID NO.1, rather than its position in the mutant.
[0074] Furthermore, the T7 RNA polymerase mutant provided by the present invention has at least 80% identity with SEQ ID NO.1, for example, it can be but not limited to at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1. As used herein, "identity" or similar terms refer to the percentage of identical nucleotides or amino acids between the sequences to be compared under optimal alignment. The percentage is purely statistical, and the differences between the two sequences may (but not necessarily) be randomly distributed over the entire length of the sequences to be compared. The comparison of two sequences is usually performed by identifying local regions of corresponding sequences relative to fragments or "comparison windows" after optimal alignment.
[0075] It is understood that a T7 RNA polymerase mutant having at least 80% identity to SEQ ID NO. 1 contains at least one of the amino acid residues at position 217 being L, at position 397 being A or W, and at position 579 being A or W.
[0076] In an optional embodiment, the T7 RNA polymerase mutant contains an amino acid residue corresponding to position 217 of the amino acid sequence shown in SEQ ID NO.1, which is L, and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1.
[0077] In an optional embodiment, the T7 RNA polymerase mutant contains an amino acid residue corresponding to position 397 of the amino acid sequence shown in SEQ ID NO.1 that is A or W, and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1, wherein position 397 is preferably W.
[0078] In an optional embodiment, the T7 RNA polymerase mutant contains an amino acid residue corresponding to position 579 of the amino acid sequence shown in SEQ ID NO.1 that is A or W, and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1, wherein position 579 is preferably W.
[0079] In an optional embodiment, the T7 RNA polymerase mutant removes at least one of the aforementioned amino acid residues and also includes at least one of the following: corresponding to the amino acid sequence shown in SEQ ID NO.1, at least one of the 369th, 430th, 633rd, 786th, 744th, 723rd and 724th positions is different from SEQ ID NO.1.
[0080] In an optional embodiment, the 633rd position corresponding to the amino acid sequence shown in SEQ ID NO.1 is a non-polar hydrophobic amino acid, preferably P (proline), L (leucine), V (valine), M (methionine) or F (phenylalanine); more preferably P, and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1. The mutation at position 633 is beneficial to improve the stability of T7 RNA polymerase.
[0081] In an optional embodiment, the 744th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is R (arginine), P (proline) or L (leucine); more preferably R; and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1. The mutation at position 744 is beneficial to the improvement of T7 RNA polymerase activity.
[0082] In an optional embodiment, the 786th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is Y (tyrosine) or a non-polar hydrophobic amino acid; more preferably Y, L (leucine), M (methionine), W (tryptophan) or F (phenylalanine); more preferably L; and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1. The mutation at position 786 is beneficial to improve the stability of T7 RNA polymerase.
[0083] In an optional embodiment, the 723rd position corresponding to the amino acid sequence shown in SEQ ID NO.1 is E (glutamic acid) or S (serine); more preferably E; and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1. The mutation at position 723 is beneficial to improve protein aggregation.
[0084] In an optional embodiment, the 369th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is T (threonine) or E (glutamic acid); and it has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1.
[0085] In an optional embodiment, the 579th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is W (tryptophan) or A (alanine); more preferably W; and has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1.
[0086] In an optional embodiment, the 430th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is P (proline); and it has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1.
[0087] In an optional embodiment, the 724th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is N (asparagine); and it has at least 80%, 85%, 90% or 95% identity with SEQ ID NO.1.
[0088] In an optional embodiment, the T7 RNA polymerase mutant is selected from any one of the following:
[0089] (a) There is at least an I217L mutation in the amino acid sequence shown in SEQ ID NO.1; that is, position 217 of SEQ ID NO.1 is mutated from isoleucine to leucine.
[0090] (b) There is at least an S397W mutation in the amino acid sequence shown in SEQ ID NO.1; that is, position 397 of SEQ ID NO.1 is mutated from serine to tryptophan.
[0091] (c) There is at least N579W mutation in the amino acid sequence shown in SEQ ID NO.1; that is, position 579 of SEQ ID NO.1 is mutated from asparagine to tryptophan.
[0092] (d) at least I217L, S397W, S430P, S633P and Q786L mutations exist in the amino acid sequence shown in SEQ ID NO.1; that is, position 217 of SEQ ID NO.1 is mutated from isoleucine to leucine, position 397 is mutated from serine to tryptophan, position 430 is mutated from serine to proline, position 633 is mutated from serine to proline, and position 786 of glutamine is mutated from leucine.
[0093] (e) at least I217L, S397W, S430P, S633P, Q786L and N579W mutations exist in the amino acid sequence shown in SEQ ID NO.1; that is, position 217 of SEQ ID NO.1 is mutated from isoleucine to leucine, position 397 is mutated from serine to tryptophan, position 430 is mutated from serine to proline, position 633 is mutated from serine to proline, position 786 is mutated from glutamine to leucine, and position 579 is mutated from asparagine to tryptophan.
[0094] (f) at least I217L, S397W, S430P, S633P, Q786L and Q744R mutations exist in the amino acid sequence shown in SEQ ID NO.1; that is, position 217 of SEQ ID NO.1 is mutated from isoleucine to leucine, position 397 is mutated from serine to tryptophan, position 430 is mutated from serine to proline, position 633 is mutated from serine to proline, position 786 is mutated from glutamine to leucine, and position 744 is mutated from glutamine to arginine.
[0095] (g) at least I217L, S397W, S430P, S633P, Q786L, C723E and A724N mutations exist in the amino acid sequence shown in SEQ ID NO.1. That is, the 217th position of SEQ ID NO.1 is mutated from isoleucine to leucine, the 397th position is mutated from serine to tryptophan, the 430th position is mutated from serine to proline, the 633rd position is mutated from serine to proline, the 786th position of glutamine is mutated from leucine, the 723rd position is mutated from cysteine to glutamic acid, and the 724th position of alanine is mutated from asparagine.
[0096] In an optional embodiment, the amino acid sequence of the T7 RNA polymerase mutant is shown as SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.15 or SEQ ID NO.17.
[0097] SEQ ID NO.3 is a T7 RNA polymerase mutant with a single point mutation I217L, with a Tm value of 50.5±0.21°C and a residual activity of 52% after treatment at 50°C for 5 minutes. Taking the enzyme activity of the wild type as 100% as a reference, the activity of the mutant is 134%.
[0098] SEQ ID NO.5 is a T7 RNA polymerase mutant with a single point mutation S397W, with a Tm value of 49.2±0.13°C and a residual activity of 47% after treatment at 50°C for 5 minutes. Taking the enzyme activity of the wild type as 100% as a reference, the activity of the mutant is 162%.
[0099] SEQ ID NO.9 is a T7 RNA polymerase mutant with a single point mutation N579W, with a Tm value of 48.0±0.23°C and a residual activity of 38% after treatment at 50°C for 5 minutes.
[0100] SEQ ID NO.11 is a T7 RNA polymerase mutant with combined mutations I217L, S397W, S430P, S633P and Q786L, with a Tm value of 54.52±0.20°C and a residual activity of 58% after heat treatment at 58°C for 15 minutes.
[0101] SEQ ID NO.13 is a T7 RNA polymerase mutant with combined mutations I217L, S397W, S430P, S633P, Q786L and N579W, with a Tm value of 55.56±0.16°C and a residual activity of 65% after heat treatment at 58°C for 15 minutes.
[0102] SEQ ID NO.15 is a T7 RNA polymerase mutant with combined mutations I217L, S397W, S430P, S633P, Q786L and Q744R, with a Tm value of 54.50±0.18°C and a residual activity of 87% after heat treatment at 58°C for 15 minutes. Taking the enzyme activity of the wild type as 100% as a reference, the activity of the mutant is 195%.
[0103] SEQ ID NO.17 is a polymerase mutant with combined mutations I217L, S397W, S430P, S633P, Q786L, C723E and A724N, with a Tm value of 54.54±0.23°C and a residual activity of 81% after heat treatment at 58°C for 15 minutes. Taking the enzyme activity of the wild type as 100% as a reference, the activity of the mutant is 183%.
[0104] According to another aspect of the present invention, the present invention also provides a polynucleotide encoding the above-mentioned T7 RNA polymerase mutant.
[0105] "Polynucleotide" herein refers to a polymer form of nucleotides of any length, including ribonucleotides and / or deoxyribonucleotides. Examples of polynucleotides include, but are not limited to, single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derived nucleotide bases. The polynucleotide encodes the above-mentioned T7 RNA polymerase mutant, and the encoding is optionally encoding the sense strand or the antisense strand. The polynucleotide can be naturally occurring, synthetic, recombinant or any combination thereof. The terms "polynucleotide" and "nucleic acid" are used interchangeably herein.
[0106] In an optional embodiment, the nucleotide sequence of the polynucleotide is shown in SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14, SEQ ID NO.16, SEQ ID NO.18, SEQ ID NO.20, SEQ ID NO.22 or SEQ ID NO.24;
[0107] Or, any one selected from the nucleotide sequences that are at least 70%, 75%, 80%, at least 90%, at least 95% or at least 98% identical to any one of SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14, SEQ ID NO.16, SEQ ID NO.18, SEQ ID NO.20, SEQ ID NO.22 and SEQID NO.24.
[0108] According to another aspect of the present invention, the present invention also provides a vector, which carries a polynucleotide encoding the above-mentioned T7 RNA polymerase mutant. The vector is well known to those skilled in the art, including but not limited to: plasmid; phagemid; Cosmid; artificial chromosome, such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); bacteriophage such as λ phage or M13 phage and animal virus, etc. Animal viruses that can be used as vectors include but are not limited to retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses. In some embodiments, the vector of the present invention contains regulatory elements commonly used in genetic engineering, such as enhancers, promoters, internal ribosome entry sites (IRES) and other expression control elements (such as transcription termination signals, or polyadenylation signals and poly-U sequences, etc.).
[0109] According to another aspect of the present invention, the present invention also provides a cell, which carries the aforementioned polynucleotide or the aforementioned vector, or expresses the aforementioned T7 RNA polymerase mutant. The cell may refer to a single cell, a cell line, or a cell culture. Cells herein include their offspring, which may not necessarily be completely identical to the primary cell due to natural, accidental or intentional mutations, and may differ from the primary cell in morphology and / or in genomic DNA. The cell may be a natural cell or a transformant.
[0110] According to another aspect of the present invention, the present invention also provides a method for synthesizing a polynucleotide, the method comprising using an enzyme system comprising the aforementioned T7 RNA polymerase mutant to catalyze a synthesis reaction. The synthesis method comprises in vitro transcription synthesis (IVT), isothermal amplification, such as sequence-specific nucleic acid in vitro amplification (NASBA) or transcription-mediated amplification (TMA).
[0111] According to another aspect of the present invention, the present invention also provides the use of the aforementioned T7 RNA polymerase mutant or the aforementioned polynucleotide synthesis method in any one of the following: at least one of mRNA vaccine preparation, nucleic acid drug preparation, gene editing and protein expression system construction, and the protein expression system construction includes but is not limited to in vivo protein expression system construction or cell-free protein expression in vitro translation system construction.
[0112] According to another aspect of the present invention, the present invention also provides a kit for polynucleotide synthesis, the kit comprising the aforementioned T7 RNA polymerase mutant. It is understandable that the kit for polynucleotide synthesis provided by the present invention may also include other detection reagents or consumables acceptable in the art, and those skilled in the art may select corresponding reagents and / or consumables according to the contents well known in the art, such as various general and more specific teaching materials, references, process manuals, product descriptions, standard documents and equipment manuals, etc. The specific optional reagents and consumables in the kit include, but are not limited to, one or more of buffers, salts, metal ions, dNTPs, enzymes, primers, probes, fluorescent dyes, luminescent substrates, reference substances, quality control substances and calibration substances.
[0113] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.
[0114] Example 1 Mutant library construction method
[0115] The recombinant vector pQE-80L-T7 RNAP ( Figure 1 ) was used as a template to amplify the T7RNAP gene. The degree of mutation was mainly determined by changing the Mn 2+ The concentration was set to 0.1mM, 0.2mM, 0.3mM, 0.4mM, 0.5mM, 0.6mM Mn 2+ Gene amplification was performed using a concentration gradient, and the optimal mutation rate was 1 to 3 mutation points per gene.
[0116] The amplification system was as follows: pQE-80L-T7 RNAP plasmid (0.2-1 ng / μL), dATP (0.25 mM), dGTP (0.25 mM), dCTP (1.05 mM), dTTP (1.05 mM), DreamTaq Buffer (Takara), DreamTaq (Takara, 0.1 U / μL), MnCl 2 (0.1mM-0.6mM), T7 RNAP-F (0.2μM), T7 RNAP-R (0.2μM).
[0117] The DNA sequence of primer T7 RNAP-F is SEQ ID NO.25: ACGAGCTCATGAACACGATTAACATCGCTAAGAAC, the DNA sequence of primer T7 RNAP-R is SEQ ID NO.26: CGAAGCTTTTACGCGAACGCGAAGTCC, the total volume of the PCR reaction system is 50 μL, and the amplification program is shown in Table 1:
[0118] Table 1 PCR amplification program
[0119]
[0120] The target fragment size was analyzed by agarose gel electrophoresis, recovered by the kit, and then double digested with BamHI and HindIII. The digested product was purified and recovered, and ligated with the linearized pQE-80L vector (double digested with BamHI and HindIII) overnight under the action of T4 DNA ligase.
[0121] The recovered ligation products were electroporated into electroporation competent E. coli 10G, and the library capacity was calculated based on the clones grown. The library capacity was 10 6 Above. At 0.2 mM Mn 2+The frequency of introduction was 1.7 base mutations / gene under 0.3 mM Mn 2+ Under the conditions, the frequency of introduction is 3.5 base mutations / gene. Therefore, in this example, 0.2 mM Mn 2+ and 0.3mMMn 2+ The mutant plasmids obtained under the above conditions were mixed to obtain a mutant library in which an average of 2.6 mutant bases were introduced into each gene.
[0122] Example 2 Screening process of mutant library
[0123] The obtained mixed plasmid mutant library was electroporated into fresh E. coli BL21 (DE3) competent cells to obtain 10 7 The entire screening process is as follows: Figure 2 As shown, Escherichia coli was induced and expressed according to the steps of protein expression, and the single cells and reaction system were encapsulated using the FADS platform. The single cell encapsulation rate was controlled at about 10% to improve the accuracy of screening. During in vitro incubation, the droplets need to be heat treated at 45°C for 7 minutes, and the activity will drop to about one-third of the original to achieve the effect of high temperature treatment, and then incubated at 37°C for 3 hours. Before using FADS to sort the mutant library, the optimal laser spot position, sorting speed and other conditions are determined by sorting FITC and ink. The incubated microdroplets are then re-injected into the detection and sorting chip.
[0124] According to the signal distribution of the mutant library, the PMT was set to 0.43V, the small and large thresholds of sorting were set to 0.2V and 0.6V respectively, and the sorting voltage was 1.6V. The droplets of about 0.42% showing the highest activity were collected in a 1.5mL centrifuge tube, and the positive genes were recovered by PCR. The target fragments were treated with BamHI and HindIII double enzymes and reconstructed into the pQE-80L linearized vector. The ligated vector was transformed into BL21 (DE3) competent cells again, and the monoclonal clones grown on the plate were picked for rescreening. In fact, in the sorting process, several rounds of sorting were carried out for different batches of transformed mutant libraries, and the obtained positive genes were mixed and recovered to ensure that more beneficial mutations could be sorted.
[0125] From the clones obtained in the previous round, about 393 fresh monoclones were picked in a 96-well plate, and three wild-type BL21 (DE3)-T7 RNAP monoclones were used as controls. After induction and expression, the crude enzyme solution was prepared by lysing the cell lysate, and the crude enzyme solution was heat-treated at 45°C for 5 minutes, quickly placed on ice, and then transferred to a 384-well plate. The enzyme activity was determined using the STAR system. Mutants whose residual activity after heat treatment was at least 1.5 times that of the wild type were sequenced. The sequencing results showed that the frequencies of mutation sites at positions 217, 397, 369, and 579 were relatively high.
[0126] Example 3 Construction of a recombinant expression vector carrying a nucleotide sequence encoding a T7 RNA polymerase mutant
[0127] The amino acid positions 217, 397, 369 and 579 of the amino acid sequence SEQ ID NO.1 of the wild-type T7 RNAP were determined as key sites, and mutants as shown in SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.15 and SEQ ID NO.17 were designed. That is, the following mutants:
[0128] Single point mutant I217L (SEQ ID NO. 3);
[0129] Single point mutant S397W (SEQ ID NO. 5);
[0130] Single point mutant M369T (SEQ ID NO. 7);
[0131] Single point mutant N579W (SEQ ID NO. 9);
[0132] Combined mutant I217L / S397W / S430P / S633P / Q786L (SEQ ID NO. 11);
[0133] Combined mutant I217L / S397W / S430P / S633P / Q786L / N579W (SEQ ID NO. 13);
[0134] Combined mutant I217L / S397W / S430P / S633P / Q786L / Q744R (SEQ ID NO. 15);
[0135] Combination mutant I217L / S397W / S430P / S633P / Q786L / C723E / A724N (SEQ ID NO. 17).
[0136] Among them, S430P, S633P and Q786L are mutation points reported in the prior art that can improve the thermal stability of T7 RNAP, Q744R is a mutation point reported in the prior art that can improve the activity of T7 RNAP (US 2015 / 0024435 A1), and the 723rd cysteine is a mutation point reported in the prior art that can improve the aggregation of T7 RNAP protein (US 9663769B2). Based on the mutation points reported in the prior art that improve thermal stability, mutants as shown in SEQ ID NO.19, SEQ ID NO.21, and SEQ ID NO.23 were designed, namely single point mutant S430P (US 7507567B2, SEQ ID NO.19), single point mutant S633P (US 7507567B2, SEQ ID NO.21) and single point mutant Q786L (CN102177236B, SEQID NO.23). Here, S430P, S633P, Q786L, Q744R, C723E are combined with the newly discovered mutation points in the present invention, hoping to obtain a T7 RNAP mutant with better thermal stability, activity and application performance than those in the prior art. The specific steps are as follows:
[0137] The amino acid sequence of SEQ ID NO.1 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.2; the amino acid sequence of SEQ ID NO.3 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.4; the amino acid sequence of SEQ ID NO.5 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.6; the amino acid sequence of SEQ ID NO.7 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.8; the amino acid sequence of SEQ ID NO.9 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.10; the amino acid sequence of SEQ ID NO.11 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.12; the amino acid sequence of SEQ ID NO.13 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.14; the amino acid sequence of SEQ ID NO.15 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.16; the amino acid sequence of SEQ ID NO.17 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.18; the amino acid sequence of SEQ ID NO.19 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.20; the amino acid sequence of SEQ ID NO.21 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.22; the amino acid sequence of SEQ ID NO.23 was reverse transcribed and optimized according to the Escherichia coli codon to obtain the nucleotide sequence SEQ ID NO.24; SEQ ID NO.2, SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14, SEQ ID NO.16, SEQ ID NO.18, SEQ ID NO.20, SEQ ID NO.22, and SEQ ID NO.24 were respectively inserted between the BamHI and HindIII restriction endonuclease sites of the pQE-80L vector to form the wild-type T7 Recombinant expression vectors of RNAP and mutant T7 RNAP.
[0138] Example 4 Construction of recombinant microbial cells expressing T7 RNA polymerase mutants
[0139] The recombinant expression vector constructed in Example 3 was transformed into BL21 (DE3) competent Escherichia coli cells to obtain recombinant strains of T7 RNAP wild type and mutants, which were named as: T7 RNAP-WT (for expressing wild type T7 RNAP), T7 RNAP-I217L (for expressing single point mutant I217L), T7 RNAP-S397W (for expressing single point mutant S397W), T7 RNAP-M369T (for expressing single point mutant M369T), T7 RNAP-N579W (for expressing single point mutant N579W), T7 RNAP-I217L / S397W / S430P / S633P / Q786L (for expressing combined mutant I217L / S397W / S430P / S633P / Q786L), T7 RNAP-I217L / S397W / S430P / S633P / Q786L / N579W (for expressing the combined mutant I217L / S397W / S430P / S633P / Q786L / N579W), T7 RNAP-I217L / S397W / S430P / S633P / Q786L / Q744R (for expressing the combined mutant I217L / S397W / S430P / S633P / Q786L / Q744R), T7 RNAP-I217L / S397W / S430P / S633P / Q786L / C723E / A724N (used to express the combined mutant I217L / S397W / S430P / S633P / Q786L / C723E / A724N), T7 RNAP-S430P (used to express the single point mutant S430P), T7 RNAP-S633P (used to express the single point mutant S633P), T7 RNAP-Q786L (used to express the single point mutant Q786L). The protein sequences of T7 RNAP expressed thereby correspond to the amino acid sequences shown in SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, SEQ ID NO.21 and SEQ ID NO.23, respectively.
[0140] Example 5 Preparation of T7 RNAP
[0141] The recombinant microbial cells expressing the wild-type and mutant T7 RNAP constructed in Example 4 were placed in LB medium containing ampicillin resistance and cultured in a shaking incubator at 37°C until the OD 600The value is close to 1.2, and then isopropyl-β-D-thiogalactopyranoside (IPTG) with a final concentration of 1 mM is added to induce expression overnight (16 hours) at 25°C shaking, followed by centrifugation at 4°C and 5000 rpm for 20 min to collect the bacterial precipitate, and then the bacteria are fully resuspended in a lysis buffer containing 300 mM NaCl, 20 mM Tris HCl (pH 7.5), 0.5 mg / mL lysozyme, and 0.5 mM DTT, and the protein lysate is centrifuged at 4°C and 18000 rpm for 1 h in a high-speed refrigerated centrifuge, and then the supernatant is separated and filtered to remove impurities. The filtered supernatant can be temporarily stored on ice for subsequent nickel column purification. Before the protein passes through the nickel column, it is necessary to balance the nickel column with 10 times the volume of elution buffer (20mMTris HCl (PH7.5), 300mM NaCl, 0.5mM DTT), and then add the previously filtered protein solution to the nickel column. After all the protein solution has passed through the nickel column filler, it is first washed with a certain concentration of Triton, and then eluted with different gradients of imidazole solution (50mM-100mM-150mM-200mM-500mM, or 50mM-100mM-150mM-500mM), and several test tubes are numbered in order of outflow to collect the outflow liquid. All the above operations must be performed on ice or at 4°C, and then all the eluted protein outflow liquid is detected by SDS PAGE electrophoresis and Coomassie Brilliant Blue staining, such as Figure 3A and Figure 3B Finally, the protein collection solution with higher concentration and better purity was comprehensively selected for ultrafiltration centrifugation, and the protein was replaced into enzyme storage buffer for storage. The enzyme storage buffer contained 50mM Tris-HCl, 100mM NaCl, 20mM 2-Mercaptoethanol, 1mM EDTA, 50% Glycerol, 0.1% Triton X-100, pH 7.9.
[0142] Example 6 Determination of relative activity of different mutants using real-time fluorescence method
[0143] The reaction system for real-time fluorescence detection of the relative enzyme activity of T7 RNAP mutants is shown in Table 2. For specific experimental methods, please refer to the Chinese patent application with application number: CN202211274914.8, and the invention name is "A detection method for real-time monitoring of in vitro transcribed RNA synthesis", in which the added protein concentration and volume of the T7 RNAP mutant are consistent with the wild type with known enzyme activity and protein concentration. The reaction is carried out in a 96-well plate, and the fluorescence value generated by the RNA aptamer produced by the reaction and the binding of DFHBI is measured in real time by an enzyme reader. The reaction system is determined according to the experimental needs. The reaction conditions are 37°C. When using an enzyme reader for real-time measurement, it takes 1 hour to measure a value every 1 minute. After the reaction is completed, the Origin software is used to draw a curve graph, and the standard curve of the protein concentration and fluorescence intensity of the wild type is calculated by taking the time with the best linear relationship, as shown in Figure 4, so as to calculate the relative activity of the mutant. All reagents in this reaction system need to be stained with Nuclease-free H 2 O, and all consumables used are RNase-free grade to prevent the produced RNA from being degraded by RNase.
[0144] Table 2 Relative activity reaction system of different mutants determined by real-time fluorescence method
[0145]
[0146] For the determination of residual activity after heat treatment at different temperatures, it is only necessary to incubate the different mutant enzymes at 50°C or 58°C for the corresponding time and then immediately transfer them to ice. The relative activities of the different enzymes can be determined at 37°C using a real-time fluorescence detection system.
[0147] The relative activity detection of the mutants is shown in Tables 3 and 4. The relative activities of the single point mutants I217L and S397W at 37°C were significantly better than those of T7 RNAP-WT and the single point mutants S430P, S633P and Q786L, and the residual activity after treatment at 50°C for 5 min was significantly higher than that of T7 RNAP-WT; the relative activity of the single point mutant M369T at 37°C was not significantly different from that of T7 RNAP-WT, and the residual activity after treatment at 50°C for 5 min was higher than that of T7 RNAP-WT; the relative activity of the single point mutant N579W at 37°C was significantly better than that of T7 RNAP-WT, and the residual activity after heat treatment at 50°C for 5 min was also higher than that of T7 RNAP-WT.
[0148] The relative activities of the combined mutants I217L / S397W / S430P / S633P / Q786L and I217L / S397W / S430P / S633P / Q786L / N579W at 37°C were not different from those of T7 RNAP-WT, but the residual activities after heat treatment at 58°C for 15 min were significantly higher than those of T7 RNAP-WT; the relative activities of the combined mutants I217L / S397W / S430P / S633P / Q786L / Q744R and I217L / S397W / S430P / S633P / Q786L / C723E / A724N at 37°C were significantly better than those of T7 RNAP-WT, and the residual activities after heat treatment at 58°C for 15 min were significantly higher than those of T7 RNAP-WT; and the residual activity of WT, single point mutant S430P, single point mutant S633P and single point mutant Q786L after treatment at 50°C for 5 minutes. The above results indicate that the T7 RNAP mutant containing I217L and S397 mutation sites has higher thermal stability than the prior art.
[0149] Table 3 Relative activities of WT and single-point mutants and residual activities after treatment at 50℃ for 5 min
[0150] T7 RNAP mutants 37℃ relative activity (%) Residual activity after treatment at 50℃ for 5 minutes (%) WT 100 18 S430P 101 34 S633P 103 30 Q786L 95 45 I217L 134 52 S397W 162 47 M369T 103 42 N579W 146 38
[0151] Table 4 Relative activities of WT and combined mutants and residual activities after treatment at 58°C for 15 min
[0152]
[0153] Example 7 Determination of Tm values of different mutants using differential scanning fluorimetry
[0154] Take 18 μL of T7 RNAP protein solution (0.2 mg / mL) and mix with 2 μL of Sypro Orange dye (100×), and dilute the protein solution and Sypro Orange dye to the required concentration with PBS. First, turn on the qPCR instrument and preheat for 20 minutes, set the lid temperature to 100°C, set the sample temperature starting point to 25°C, the heating rate to 0.5°C / s, wait for 5 seconds, and then cycle 120 times to 85°C. Set the filter to the Sypro Orange channel and take the average of 10 samples. The Tm of a protein is an indicator of thermal stability. Generally speaking, the higher the Tm, the more stable the protein.
[0155] The Tm values of different mutants are shown in Table 5 , single point mutant I217L, single point mutant S397W, combined mutant I217L / S397W / S430P / S633P / Q786L, combined mutant I217L / S397W / S430P / S633P / Q786L / N579W, combined mutant I217L / S397W / S430P / S633P / Q786L / N579W. The Tm values of 33P / Q786L / Q744R and the combined mutant I217L / S397W / S430P / S633P / Q786L / C723E / A724N are higher than those of WT and the single point mutants S430P, S633P, and Q786L; the Tm values of the single point mutant M369T and the single point mutant N579W are higher than those of WT. The above results indicate that the T7 RNAP mutant provided by the present invention has higher thermal stability than that of the prior art.
[0156] Table 5 Tm values of different mutants
[0157] T7 RNAP mutants Tm(℃) WT 46.5±0.15 S430P 48.9±0.13 S633P 47.1±0.12 Q786L 47.3±0.09 I217L 50.5±0.21 S397W 49.2±0.13 M369T 49.0±0.14 N579W 48.0±0.23 I217L / S397W / S430P / S633P / Q786L 54.52±0.20 I217L / S397W / S430P / S633P / Q786L / N579W 55.56±0.16 I217L / S397W / S430P / S633P / Q786L / Q744R 54.50±0.18 I217L / S397W / S430P / S633P / Q786L / C723E / A724N 54.54±0.23
[0158] Example 8 Comparison of IVT yield and product purity of T7 RNAP mutants and wild type at different temperatures
[0159] The in vitro transcription (IVT) reaction system is shown in Table 6. The reaction system can be scaled up in equal proportions. After the system configuration is completed, it is placed at 37°C and 50°C for 2 h, respectively. Then, 10 U DNaseI is added to each reaction according to 1 μg of template and reacted at 37°C for 30 min to digest the DNA template. The IVT product is then recovered by the LiCl precipitation method, the RNA concentration is determined, and the mRNA yield (μg) corresponding to the IVT yield-1 μg template DNA is calculated. The product purity is determined by the Qsep-100 fully automatic nucleic acid protein analysis system.
[0160] Table 6 In vitro transcription reaction system
[0161] Reagents DNA template 1 μg T7 RNAP (0.5 mg / mL) 2μL ATP / CTP / GTP / N1-Me-pUTP(100mM each) 2μL each Cap1(3'OH AG)(100mM) 1.6μL RNase inhibitor (40U / μL) 1μL Inorganic pyrophosphatase (0.1U / μL) 0.4μL 10× In vitro Transcription Buffer 2μL <![CDATA[Nuclease-free(NF)H 2 The]]> Make up to 20 μL
[0162] IVT yield - mRNA yield (μg) corresponding to 1μg template DNA is shown in Table 7. The IVT yield of the single point mutant I217L at 37°C was not significantly different from that of WT, but the IVT yield at 50°C was increased by 67% compared with that of WT at 37°C; there was no significant difference in the IVT yield of the single point mutant I217L and the single point mutants S430P, S633P and Q786L at 37°C and 50°C; the IVT yield of the single point mutant S397W at 37°C and 50°C was Compared with WT and single point mutants S430P, S633P and Q786L, there is a certain degree of improvement; the IVT yield of the combined mutant I217L / S397W / S430P / S633P / Q786L at 37°C has no significant difference compared with WT and single point mutants S430P, S633P, Q786L, but the IVT yield at 50°C is higher than that of WT at 37°C and single point mutants I217L, S397W, S430P, S633P, Q786L at 50°C. The IVT yield of the combined mutant I217L / S397W / S430P / S633P / Q786L / N579W at 50°C was 60% higher than that of WT at 37°C. The IVT yield of the combined mutant I217L / S397W / S430P / S633P / Q786L / Q744R at both 37°C and 50°C was significantly higher than that of WT and the single point mutants I217L, S397W, S430P, S633P, Q786L, and Q744R. The combined mutant I217L / S397W / S430P / S633P / Q786L / C723E / A724N increased the IVT yield of the combined mutant I217L / S397W / S430P / S633P / Q786L / C723E / A724N at 37°C by about 20% compared with WT and single-point mutants I217L, S430P, S633P, and Q786L, and the IVT yield of the combined mutant I217L / S397W / S430P / S633P / Q786L at 37°C by about 120% compared with WT and single-point mutants I217L, S430P, S633P, and Q786L at 50°C. The above results show that the T7 RNAP mutants provided in the above embodiments have better IVT application performance under high temperature conditions than the prior art, and can produce higher yield products.
[0163] Table 7 IVT production
[0164] T7 RNAP mutants 37℃(μg) 50℃(μg) WT 92.84 - S430P 89.88 149.88 S633P 93.96 138.72 Q786L 76.29 126.31 I217L 90.12 155.22 S397W 123.42 175.33 I217L / S397W / S430P / S633P / Q786L 96.09 205.06 I217L / S397W / S430P / S633P / Q786L / N579W 87.89 149.22 I217L / S397W / S430P / S633P / Q786L / Q744R 143.02 210.24 I217L / S397W / S430P / S633P / Q786L / C723E / A724N 110.70 202.14
[0165] As shown in Table 8, the purity of the combined mutants I217L / S397W / S430P / S633P / Q786L and the combined mutants I217L / S397W / S430P / S633P / Q786L / N579W at 37°C in the IVT product reaction was significantly improved compared with the WT and the single point mutants I217L, S397W, S430P, S633P, and Q786L, and the product purity improvement rate was more than 10%; The product purity of the combined mutants I217L / S397W / S430P / S633P / Q786L / Q744R and the combined mutants I217L / S397W / S430P / S633P / Q786L / C723E / A724N reacted at 37°C was significantly improved compared with WT and single point mutants I217L, S397W, S430P, S633P, and Q786L, and the product purity improvement rate was all above 5%. The combined mutants I217L / S397W / S430P / S633P / Q786L, the combined mutants I217L / S397W / S430P / S633P / Q786L / N579W, the combined mutants I217L / S397W / S430P / S633P / Q786L / Q744R, and the combined mutants I217L / S397W / S430P / S633 The purity of the IVT product of P / Q786L / C723E / A724N at 50°C is within 5% relative to the purity of the IVT product of WT and single point mutants I217L, S397W, S430P, S633P, Q786L at 37°C and single point mutants I217L, S397W, S430P, S633P, Q786L at 50°C, and it is considered that there is no significant difference. This shows that the purity of the IVT product of the T7 RNAP mutant provided by the present invention is improved to a certain extent compared with the prior art.
[0166] Table 8 IVT product purity
[0167] T7 RNAP mutants 37℃ reaction 50℃ reaction WT 69.3% - S430P 70.8% 64.2% S633P 72.2% 68.7% Q786L 71.2% 67.3% I217L 71.3% 69.4% S397W 73.1% 70.2% I217L / S397W / S430P / S633P / Q786L 84.5% 68.9% I217L / S397W / S430P / S633P / Q786L / N579W 82.7% 73.0% I217L / S397W / S430P / S633P / Q786L / Q744R 79.4% 68.5% I217L / S397W / S430P / S633P / Q786L / C723E / A724N 77.4% 67.4%
[0168] Example 9 Comparison of dsRNA content in IVT products of T7 RNAP mutants and wild type at different temperatures
[0169] The dsRNA content in the IVT product was detected by dot blot. First, the IVT RNA sample recovered by LiCl precipitation in Example 8 was added dropwise to the positively charged Hybond N membrane (GE Amersham), and then the membrane was blocked in 5% (w / v) skim milk powder TBS-T buffer (20mM Tris, pH 7.4, 150mM NaCl, 0.1% [v / v] Tween-20). Then, J2 anti-dsRNA antibody (1:5000 dilution; incubated overnight at 4°C. The blot was detected with HRP-conjugated secondary antibody (Cell Signaling Technologies). A dsRNA standard of known concentration was used as a positive control.
[0170] The experimental results are as follows Figure 5 As shown, when the mRNA loading amount was the same, dot blot analysis showed that the dsRNA byproduct content in the IVT products of single point mutants I217L, S397W, S430P, S633P, Q786L, combination mutants I217L / S397W / S430P / S633P / Q786L, combination mutants I217L / S397W / S430P / S633P / Q786L / N579W, combination mutants I217L / S397W / S430P / S633P / Q786L / Q744R, and combination mutants I217L / S397W / S430P / S633P / Q786L / C723E / A724N at 50°C was significantly lower than that in the IVT product of WT at 37°C. This indicates that the T7 RNAP mutant provided in the above examples has a significantly improved dsRNA content in the IVT product compared to the wild type in the prior art through high temperature reaction.
[0171] Example 10 3' consistency detection of IVT products of T7 RNAP mutant and wild type at different temperatures
[0172] The 3' consistency detection of IVT products is achieved by RNase T1 digestion experiment. RNase T1 can specifically degrade single-stranded RNA at the G residue, which cuts the phosphodiester bond between the 3'-guanosine residue and the 5'-OH residue of the adjacent nucleotide by forming the corresponding intermediate 2', 3'-cyclic phosphate (-mP) salt; the reaction products are 3'-GMP and oligonucleotides containing terminal 3'-GMP. Then, the molecular weight of the 3'-terminal product is analyzed by LC-MS and compared with the theoretical molecular weight. If the 3' end of the normal mRNA product is a G base ending with -OH, then the 3' end G base of the heterogeneous product ends with -mP, and the molecular weight of the heterogeneous product is 80 more than that of the normal product. The 3' end consistency (%) is calculated by analyzing the proportion of the theoretical molecular weight product, and the heterogeneity (%) is 3'-consistency.
[0173] The experimental results are shown in FIG6 . The molecular weight of the 3' end consistent product is 9663.1, and the molecular weight of the 3' end heterogeneous product is 9743.1. Data analysis As shown in Table 9, the 3' end consistency products of single point mutants I217L, S397W, S430P, S633P, Q786L, and combination mutants I217L / S397W / S430P / S633P / Q786L, combination mutants I217L / S397W / S430P / S633P / Q786L / N579W, combination mutants I217L / S397W / S430P / S633P / Q786L / Q744R and combination mutants I217L / S397W / S430P / S633P / Q786L / C723E / A724N reacted at 50°C had significantly better 3' end consistency products than the WT reacted at 37°C. This indicates that the T7 RNAP mutant provided by the present invention has significantly improved uniformity of IVT products compared with the wild type in the prior art through high temperature reaction.
[0174] Table 9 IVT product 3' end consistency
[0175] T7 RNAP mutants 37℃ reaction 50℃ reaction WT 3.60% - S430P 0% 13.43% S633P 0% 14.74% Q786L 0% 15.50% I217L 2.64% 15.40% S397W 4.61% 13.64% I217L / S397W / S430P / S633P / Q786L 0% 21.11% I217L / S397W / S430P / S633P / Q786L / N579W 0% 19.50% I217L / S397W / S430P / S633P / Q786L / Q744R 0% 19.77% <h2 style=";text-align:left;direction:ltr">I217L / S397W / S430P / S633P / Q786L / C723E / A724N 0% 18.37%
[0176] Example 11 Determination of relative activities of different mutants
[0177] The experimental method is the same as that of Example 6. The following mutants were tested: single point mutant S397A, single point mutant Q786W, single point mutant Q786M and single point mutant Q786F. The mutants of this example were obtained by single point mutation of the wild-type T7 RNAP whose amino acid sequence is shown in SEQ ID NO.1. The construction method of the mutants of this example is the same as that of Examples 3 to 5. The test results are shown in Table 10.
[0178] Table 10
[0179]
[0180] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A T7 RNA polymerase mutant, It is characterized in that Corresponding to the amino acid sequence shown in SEQ ID NO.1, there is at least one of the following amino acid residues: L at position 217, A or W at position 397, and A or W at position 579; Furthermore, it has at least 80% identity with SEQ ID NO.
1.
2. The T7 RNA polymerase mutant according to claim 1, It is characterized in that The T7 RNA polymerase mutant further comprises at least one of the following amino acid residues: corresponding to the amino acid sequence shown in SEQ ID NO.1, at least one of positions 369, 430, 633, 786, 744, 723 and 724 is different from SEQ ID NO.1; Preferably, the 633rd position corresponding to the amino acid sequence shown in SEQ ID NO.1 is a non-polar hydrophobic amino acid; more preferably, it is P, L, V, M or F; and even more preferably, it is P; Preferably, the 744th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is R, P or L; more preferably R; Preferably, the 786th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is Y or a non-polar hydrophobic amino acid; more preferably Y, L, M, W or F; and even more preferably L; Preferably, the 723rd position corresponding to the amino acid sequence shown in SEQ ID NO.1 is E or S; more preferably, E; Preferably, position 369 corresponding to the amino acid sequence shown in SEQ ID NO.1 is T or E; Preferably, the 430th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is P; Preferably, the 724th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is N; Preferably, the 397th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is W; Preferably, the 579th position corresponding to the amino acid sequence shown in SEQ ID NO.1 is W.
3. The T7 RNA polymerase mutant according to claim 1 or 2, It is characterized in that Choose from any of the following: (a) at least one I217L mutation is present in the amino acid sequence shown in SEQ ID NO.1; (b) at least S397W mutation is present in the amino acid sequence shown in SEQ ID NO.1; (c) at least N579W mutation is present in the amino acid sequence shown in SEQ ID NO.1; (d) at least I217L, S397W, S430P, S633P and Q786L mutations are present in the amino acid sequence of SEQ ID NO.1; (e) at least I217L, S397W, S430P, S633P, Q786L and N579W mutations are present in the amino acid sequence of SEQ ID NO.1; (f) at least I217L, S397W, S430P, S633P, Q786L and Q744R mutations are present in the amino acid sequence of SEQ ID NO.1; (g) at least I217L, S397W, S430P, S633P, Q786L, C723E and A724N mutations are present in the amino acid sequence of SEQ ID NO.1; Preferably, the amino acid sequence of the T7 RNA polymerase mutant is shown in SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.15 or SEQ ID NO.
17.
4. A polynucleotide encoding the T7 RNA polymerase mutant according to any one of claims 1 to 3; Preferably, the nucleotide sequence of the polynucleotide is shown as SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14, SEQ ID NO.16, SEQ ID NO.18, SEQ ID NO.20, SEQ ID NO.22 or SEQ ID NO.24; Or, any one selected from the nucleotide sequences that are at least 70% identical to any one of SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14, SEQ ID NO.16, SEQ ID NO.18, SEQ ID NO.20, SEQ ID NO.22 and SEQ ID NO.
24.
5. Carrier, It is characterized in that The vector carries the polynucleotide according to claim 4.
6. Cells, It is characterized in that The cell carries the polynucleotide according to claim 4 or the vector according to claim 5, or expresses the T7 RNA polymerase mutant according to any one of claims 1 to 3.
7. Screening method for T7 RNA polymerase mutants, It is characterized in that The method comprises amplifying a polynucleotide encoding T7 RNA polymerase in a reaction system containing 0.1 to 0.6 mM manganese ions, then transforming a vector carrying the amplified product into cells, inducing expression in the cells and sorting target cells using a droplet microfluidic cell sorting method; in an in vitro incubation step of the droplet microfluidic cell sorting, heat-treating the droplets; Preferably, the heat treatment is carried out at 40-50°C for 5-10 minutes; Preferably, the heat treatment condition is 45°C for 7 minutes; Preferably, the concentration of manganese ions in the reaction system is 0.2 mM to 0.3 mM; Preferably, the target cells are 0.4% to 0.45% of the droplet-encapsulated cells that exhibit the highest viability; Preferably, the amplified polynucleotide encoding T7 RNA polymerase and the nucleotide sequence are shown as SEQ ID NO.2; Preferably, the method further comprises at least one step: separating the target fragments from the target cells sorted by the droplet microfluidic cell sorting method, transforming the fragments into another cell, and screening the cells again after culturing; Preferably, the T7 RNA polymerase mutants expressed by the positive cells are collected, the system containing the T7 RNA polymerase mutants is heat-treated, and then the enzyme activity is determined, and the positive clones whose enzyme activity is at least 1.5 times that of the wild type are sequenced.
8. A method for synthesizing a polynucleotide, It is characterized in that The method comprises using an enzyme system comprising the T7 RNA polymerase mutant according to any one of claims 1 to 3 to catalyze a synthesis reaction; Preferably, the synthesis method comprises in vitro transcription synthesis, isothermal amplification or transcription-mediated amplification.
9. Use of the T7 RNA polymerase mutant according to any one of claims 1 to 3, or the method for synthesizing a polynucleotide according to claim 8 in any one of the following: at least one of mRNA vaccine preparation, nucleic acid drug preparation, gene editing, and protein expression system construction.
10. A kit for polynucleotide synthesis, It is characterized in that The invention comprises the T7 RNA polymerase mutant according to any one of claims 1 to 3.
Citation Information
Cited By
T7 RNA polymerase mutant and application thereof
CN119464247A
Heat-resistant high-yield T7 RNA polymerase mutant as well as preparation method and application thereof
CN119752838A
T7 RNA polymerase and preparation method thereof
CN120818505A
